CRIS Current Research Information System

PAPAYANNIDIS, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 21.890
NA - Nord America 19.174
EU - Europa 15.180
AF - Africa 1.333
SA - Sud America 1.163
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 17
Totale 58.790
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.895
VN - Vietnam 6.277
SG - Singapore 5.507
CN - Cina 5.432
GB - Regno Unito 3.980
IT - Italia 2.323
SE - Svezia 2.223
DE - Germania 1.832
HK - Hong Kong 1.375
IN - India 1.010
FR - Francia 970
BR - Brasile 822
RU - Federazione Russa 737
NL - Olanda 625
KR - Corea 533
IE - Irlanda 523
JP - Giappone 423
ZA - Sudafrica 383
FI - Finlandia 344
UA - Ucraina 316
TG - Togo 289
EE - Estonia 268
CI - Costa d'Avorio 223
CH - Svizzera 205
CA - Canada 181
GR - Grecia 177
NG - Nigeria 172
JO - Giordania 161
BG - Bulgaria 158
AR - Argentina 154
PH - Filippine 146
SC - Seychelles 130
BD - Bangladesh 115
IR - Iran 112
ID - Indonesia 104
IQ - Iraq 103
BE - Belgio 97
TR - Turchia 96
TH - Thailandia 93
PL - Polonia 85
AT - Austria 77
ES - Italia 70
TW - Taiwan 64
MX - Messico 58
UZ - Uzbekistan 54
PK - Pakistan 53
EC - Ecuador 42
SA - Arabia Saudita 38
MY - Malesia 35
LB - Libano 29
VE - Venezuela 28
AU - Australia 27
CL - Cile 26
HR - Croazia 26
PY - Paraguay 26
CO - Colombia 24
EG - Egitto 24
TN - Tunisia 22
MA - Marocco 20
CZ - Repubblica Ceca 19
LT - Lituania 19
PE - Perù 19
RO - Romania 18
AE - Emirati Arabi Uniti 15
KE - Kenya 15
DZ - Algeria 14
KZ - Kazakistan 14
EU - Europa 12
IL - Israele 12
RS - Serbia 12
ET - Etiopia 11
NP - Nepal 11
OM - Oman 11
UY - Uruguay 11
AZ - Azerbaigian 10
PT - Portogallo 10
MK - Macedonia 9
SK - Slovacchia (Repubblica Slovacca) 9
TM - Turkmenistan 9
QA - Qatar 8
TT - Trinidad e Tobago 8
AL - Albania 7
KG - Kirghizistan 7
MU - Mauritius 7
BA - Bosnia-Erzegovina 6
GY - Guiana 6
JM - Giamaica 6
NO - Norvegia 6
NZ - Nuova Zelanda 6
PS - Palestinian Territory 6
BY - Bielorussia 5
LV - Lettonia 5
PA - Panama 5
BB - Barbados 4
CY - Cipro 4
DK - Danimarca 4
GH - Ghana 4
HN - Honduras 4
HU - Ungheria 4
SI - Slovenia 4
Totale 58.718
Salva come PNG Salva come JPEG
Città #
Singapore 3.832
Southend 3.646
Ashburn 2.040
Chandler 1.626
Fairfield 1.483
Dong Ket 1.344
Hong Kong 1.294
Ho Chi Minh City 1.194
San Jose 1.165
Hanoi 1.014
Hefei 967
Houston 897
Beijing 815
Wilmington 794
Woodbridge 737
Ann Arbor 709
Seattle 685
Santa Clara 679
Princeton 654
Dublin 518
Cambridge 513
Boardman 499
Seoul 430
Bologna 402
Lauterbourg 355
Nanjing 323
Tokyo 322
Westminster 322
Lomé 289
Padova 285
Los Angeles 282
New York 273
Helsinki 266
Dallas 240
Medford 230
Abidjan 223
Milan 200
Bern 167
Frankfurt am Main 167
Haiphong 164
Shenyang 159
Amman 156
Sofia 153
Jinan 149
Da Nang 146
Saint Petersburg 143
Berlin 142
Munich 141
Buffalo 139
Redondo Beach 135
Redmond 126
São Paulo 126
Hebei 120
Nanchang 115
Abeokuta 111
Guangzhou 111
Turin 108
Bremen 105
Changsha 104
Shanghai 99
San Diego 98
Bengaluru 95
Brussels 93
Redwood City 91
Council Bluffs 89
Florence 88
Tianjin 84
Zhengzhou 78
Falls Church 77
Rome 76
Jacksonville 73
Jiaxing 71
Johannesburg 68
Amsterdam 65
Hải Dương 64
Biên Hòa 63
Toronto 61
Hangzhou 60
Norwalk 57
Nuremberg 57
Orem 54
Baghdad 53
Jakarta 53
London 52
Phoenix 52
Falkenstein 51
Chicago 50
Warsaw 50
Vienna 47
Can Tho 46
Paris 44
Ningbo 43
Turku 43
Haikou 42
Hyderabad 41
Athens 40
Mountain View 40
Taiyuan 40
Montreal 39
Brooklyn 38
Totale 37.059
Salva come PNG Salva come JPEG
Nome #
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 656
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 381
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 348
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 341
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 335
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 315
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 311
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 310
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 303
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 291
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 289
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 281
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 275
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 272
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 266
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 258
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 257
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 253
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 252
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 252
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 252
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 250
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 249
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 248
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 246
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 244
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia 240
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 240
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 235
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma 232
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 232
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 231
Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data 231
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 230
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 229
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 228
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 228
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 227
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 226
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 225
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 225
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 224
Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Coronary Artery Disease and in Centenarians. Further Clues Linking Chip with Cardiovascular Risk 224
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 223
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 222
A case report of acute myeloid leukemia and neurofibromatosis 1 220
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 219
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 217
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 217
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 216
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 215
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 215
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 215
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 214
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 214
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 211
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 211
Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial 209
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 209
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 209
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 208
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 208
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 208
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 207
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 207
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis 204
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 202
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 202
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 201
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 201
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 200
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 200
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 200
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 198
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 198
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 198
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 198
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 197
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 197
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 197
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 196
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 196
Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations 196
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 196
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 195
Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. 195
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis 194
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 194
Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 193
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 193
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 191
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 191
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 189
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 188
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 188
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 188
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 188
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway 187
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 186
Totale 23.324
Salva come PNG Salva come JPEG
Categoria #
all - tutte 149.681
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 149.681
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.620 0 0 0 0 0 0 0 0 0 198 206 2.216
2021/20226.614 650 151 413 592 663 438 133 425 345 463 1.167 1.174
2022/20237.108 820 1.089 362 913 532 519 249 400 1.148 159 554 363
2023/20242.002 94 296 109 184 133 422 120 142 119 129 134 120
2024/20258.374 325 1.249 662 538 1.146 392 746 271 113 757 482 1.693
2025/202619.758 1.810 2.536 1.709 1.414 2.061 1.098 1.937 947 4.595 1.651 0 0
Totale 59.936